RSV Prevention in Latin America and the Caribbean: Proven Immediate Benefits and Potential Life-Course Value
Vaccines · 18.11.2026 · 14 (11) · 995
DOI: 10.3390/vaccines14110995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 18.11.2026. Verfasst von Roberto Debbag und 27 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Latin American Society for Vaccinology.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) remains a leading cause of infant lower respiratory tract infection, hospitalization, and death in Latin America and the Caribbean, where unequal access to diagnosis, medical care, oxygen, referral, and intensive care worsens outcomes. New passive immunization tools, maternal RSV prefusion F vaccination and long-acting monoclonal antibodies, can protect infants before peak vulnerability. Still, their population impact depends on timing, coverage, equity, financing, surveillance, and program design. Emerging regional experience with hybrid strategies may help close protection gaps among infants missed or insufficiently protected by maternal immunization. Severe early-life RSV disease is consistently associated with recurrent lower respiratory tract infections, wheezing, asthma, impaired lung-function trajectories, and increased health-care use. However, causality and long-term effects of current preventive products remain uncertain. A regional agenda linking maternal–infant cohorts, surveillance, equity analyses, and long-term health-economic evaluations is needed to define both the established immediate and potential longer-term public-health value of RSV prevention.
Förderung
- Latin American Society for Vaccinology
Zitieren
APA
Debbag, R., Ávila-Agüero, M. L., Brea, J., Kfouri, R. D. Á., Muñoz, F. M., Marc, G. P., Castilla, E. M. R. D., Torres-Martinez, C. N., Gutierrez-Tobar, I. F., Beltran-Arroyave, C., Arias-Sanchez, A., Benítez, I., Bonilla, J. E., Castellano, V., Dueñas, L., Estripeaut, D., Gutiérrez, V., Jacinto, L., Juárez, M. D. V., …, & Rodríguez-Morales, A. J. (2026). RSV Prevention in Latin America and the Caribbean: Proven Immediate Benefits and Potential Life-Course Value. Vaccines, 14(11), 995. https://doi.org/10.3390/vaccines14110995
Vancouver
Debbag R, Ávila-Agüero ML, Brea J, Kfouri RDÁ, Muñoz FM, Marc GP, et al. RSV Prevention in Latin America and the Caribbean: Proven Immediate Benefits and Potential Life-Course Value. Vaccines. 2026;14(11):995. doi:10.3390/vaccines14110995
BibTeX
@article{Debbag2026,
author = {Debbag, Roberto and Ávila-Agüero, María L. and Brea, José and Kfouri, Renato de Ávila and Muñoz, Flor M. and Marc, Gonzalo Pérez and Castilla, Eva María Ruiz de and Torres-Martinez, Carlos N. and Gutierrez-Tobar, Ivan F. and Beltran-Arroyave, Claudia and Arias-Sanchez, Andrés and Benítez, Irene and Bonilla, J. Esteban and Castellano, Vanesa and Dueñas, Lourdes and Estripeaut, Dora and Gutiérrez, Valentina and Jacinto, Lesly and Juárez, María del Valle and Lazo, Gustavo and Mayrides, Maurice and Palmieri, Melissa and Parra-Buitrago, Andrea and Pujadas, Mónica and Ramírez, Jesús Moisés and Rapaport, Solana and Zambrano, Gabriela and Rodríguez-Morales, Alfonso J.},
title = {RSV Prevention in Latin America and the Caribbean: Proven Immediate Benefits and Potential Life-Course Value},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {995},
doi = {10.3390/vaccines14110995}
}
EUVIMED